The CARAVAN study (GS-US-540-5823) was a single-arm, open-label, phase 2/3 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of up to 10 days of treatment with VEKLURY in pediatric patients (N=58) hospitalized with mild, moderate, or severe COVID-19 and confirmed SARS-CoV-2 infection. Pediatric patients, from birth (including preterm to infants) to <18 years of age and weighing ≥1.5 kg, were evaluated by age and weight. Recovery was defined as an improvement from baseline clinical status score of 2 through 5 to a score of 6 or 7, or an improvement from a baseline score of 6 to a score of 7, on a 7-point ordinal scale.
GA=gestational age.
Characteristic | VEKLURY(n=53) | ||
---|---|---|---|
Median age (IQR), y | 7 (2-12) | ||
Median weight (range), kg | 25 (4-192) | ||
Female sex, % | 57 | ||
Race or ethnic group, % | |||
White | 70 | ||
Black | 30 | ||
Hispanic or Latinx | 44 | ||
Respiratory support at baseline, n (%) | |||
Invasive mechanical ventilation | 12 (23) | ||
Noninvasive ventilation or high-flow oxygen | 18 (34) | ||
Low-flow oxygen | 10 (19) | ||
Room air | 13 (25) | ||
Overall median duration of symptoms (IQR), days | 5 (3-7) | ||
Hospitalization prior to first dose of VEKLURY (IQR), days | 1 (1-3) |
IQR=interquartile range.
Characteristic | VEKLURY(n=5) | ||
---|---|---|---|
Age range, days | 12-30 | ||
Weight range, kg | 2.2-3.5 | ||
Female sex, n | 3 | ||
Race, n | |||
White | 4 | ||
Black | 1 | ||
Respiratory support at baseline, n | |||
Invasive mechanical ventilation | 3 | ||
High-flow oxygen | 2 | ||
Duration of symptoms range, days | 2-9 | ||
Hospitalization prior to first dose of VEKLURY range, days | 1-9 |
Patient clinical status was assessed on a 7-point ordinal scale with a lower score indicating greater clinical severity.
ECMO=extracorporeal membrane oxygenation.
Tap for Important Safety Information, including contraindication for history of clinically significant hypersensitivity to VEKLURY.
VEKLURY is indicated for the treatment of COVID-19 in adults and pediatric patients (birth to <18 years of age weighing ≥1.5 kg, who are hospitalized, or not hospitalized, with mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death.
Contraindication
Warnings and precautions
Adverse reactions
Dosage and administration
Pregnancy and lactation
VEKLURY is indicated for the treatment of COVID-19 in adults and pediatric patients (birth to <18 years of age weighing ≥1.5 kg), who are hospitalized, or not hospitalized, with mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death.
Please see full Prescribing Information for VEKLURY.
Tap for Important Safety Information, including contraindication for history of clinically significant hypersensitivity to VEKLURY.
VEKLURY is indicated for the treatment of COVID-19 in adults and pediatric patients (birth to <18 years of age weighing ≥1.5 kg, who are hospitalized, or not hospitalized, with mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death.
Contraindication
Warnings and precautions
Adverse reactions
Dosage and administration
Pregnancy and lactation
VEKLURY is indicated for the treatment of COVID-19 in adults and pediatric patients (birth to <18 years of age weighing ≥1.5 kg), who are hospitalized, or not hospitalized, with mild-to-moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death.
Please see full Prescribing Information for VEKLURY.
*Patients evaluated in the infants, children, and adolescent cohorts were aged ≥28 days to <18 years and ranged in weight, starting from ≥3 kg.
†Patients evaluated in the neonate and infant cohorts included term neonates, preterm neonates, and infants. Term neonatal patients ranged in age (from birth to <28 days) and weight (≥2.5 kg at birth or screening). Preterm neonates and infants ranged in age (from birth to <56 days) and weight (≥1.5 kg at birth).